Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.49 |
| ▸ | NPC1L1 | Q9UHC9 | 8/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.32 |
| ▸ | BDKRB2 | P30411 | 3/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14282652 | 0.96 | GRIN2B (0.50) | GRIN2BGRIN2CNPC1L1CDK4CTSK | |
| SCHEMBL15937072 | 0.90 | GRIN2B (0.55) | GRIN2BGRIN2CNPC1L1CDK4CTSK | |
| SCHEMBL24339456 | 0.89 | GRIN2B (0.54) | GRIN2BGRIN2CNPC1L1CDK4CTSK | |
| SCHEMBL5134369 | 0.88 | GRIN2B (0.47) | GRIN2BGRIN2CNPC1L1CDK4CTSK | |
| SCHEMBL25852386 | 0.87 | GRIN2B (0.51) | GRIN2BGRIN2CNPC1L1CDK4CTSK | |
| SCHEMBL14282651 | 0.84 | GRIN2B (0.48) | GRIN2BGRIN2CNPC1L1CDK4CTSK | |
| SCHEMBL15937192 | 0.81 | BDKRB2 (0.38) | BDKRB2 | |
| SCHEMBL24112192 | 0.80 | GRIN2B (0.57) | GRIN2BGRIN2CCDK4CTSKJAK3 | |
| SCHEMBL1948718 | 0.79 | KMT2A (0.52) | GRIN2BGRIN2CNPC1L1 | |
| SCHEMBL15937196 | 0.78 | GRIN2B (0.53) | GRIN2BGRIN2CNPC1L1CDK4CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064643-A1 | Myd88 Homodimerization Inhibitors | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064643-A1 | Myd88 Homodimerization Inhibitors | MYD88, TLR4, TLR6 | GRIN2B 2563/4885GRIN2C 3043/4885NPC1L1 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.